AhmannPA, WaltonenSJ, OlsonKA, TheyeFW, Van EremAJ, LaPlantRJ: Placebo-controlled evaluation of Ritalin side effects. Pediatrics, 91:1101–1106, 1993.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
3.
AnfossiG, MassuccoP, MularoniE, CavalotF, BurzaccaS, MattielloL, TrovatiM: Studies on the effect of dopamine on the human platelet response. Clin Exp Pharmacol Physiol, 19:613–618, 1992.
4.
BraunsteinKM, SarjiKE, KleinfelderJ, SchraibmanHB, ColwellJA, EureniusK: The effect of dopamine on human platelet aggregation, in vitro. J Pharmacol Exp Ther, 200:449–457, 1977.
5.
CoskunM, AdakI: Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder. J Clin Psychopharmacol, 37:637–639, 2017.
6.
GreenWH: Sympathomimetic amines and central nervous system stimulants. In: MitchellCW, KairisL (eds). Child and Adolescent Clinical Psychopharmacology (4th ed.). Philadelphia, PA, Lippincott Williams & Wilkins, 2007, pp. 55–90.
7.
GreenhillLL: Clinical effects of stimulant medication in attention-deficit/hyperactivity disorder (ADHD). In: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Edited by SolantoMV, ArnstenAFT, CastellanosFX. New York, Oxford University Press, 2001, pp. 31–71.
8.
GrossmanLK, GrossmanNJ: Methylphenidate and idiopathic thrombocytopenic purpura—Is there an association?. J Fam Pract, 20:302–304, 1985.
9.
KupermanAA, YanivI, StahlB, TamaryH: Methylphenidate as a possible cause of thrombocytopenia. Ann Pharmacother, 37:1146, 2003.
10.
McEvoyGK: AHFS Drug Information. Bethesda (Maryland), American Society of Health System Pharmacists, 2002, pp. 2348–2353.
11.
PyoMK, Yun-ChoiHS, HongYJ: Apparent heterogeneous responsiveness of human platelet rich plasma to catecholamines. Platelets, 14:171–178, 2003.
12.
SchedelA, SchlossP, KlüterH, BugertP: The dopamine agonism on ADP-stimulated platelets is mediated through D2-like but not D1-like dopamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol, 378:431–439, 2008.
13.
StorebøOJ, RamstadE, KroghHB, NilausenTD, SkoogM, HolmskovM, RosendalS, GrothC, MagnussonFL, Moreira-MaiaCR, GilliesD, Buch RasmussenK, GauciD, ZwiM, KirubakaranR, ForsbølB, SimonsenE, GluudC: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev, 11:CD009885, 2015.
14.
VolkowND, WangGJ, FowlerJS, GatleySJ, LoganJ, DingYS, HitzemannR, PappasN: Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry, 155:1325–1331, 1998.
